TEVA-TRIACOMB

Adverse Drug Reaction Overview The following adverse skin reactions have been reported with the use of topical corticosteroids: dryness, itching, burning, local irritation, skin atrophy, striae, atrophy of subcutaneous tissue, folliculitis, acneiform eruptions, hypertrichosis, change in skin pigmentation and telangiectasia.

Adrenal suppression has also been reported following topical corticosteroid therapy. Posterior subcapsular cataracts have been observed following systemic corticosteroid therapy. Hypersensitivity reactions to neomycin, gramicidin, and nystatin have been reported.

Systemic neomycin toxicity has occurred rarely following topical administration; tinnitus and deafness have also been reported. Overgrowth of non-susceptible organisms has occurred. 25 mg. Apply a small quantity two or three times daily.

Do not apply more than prescribed by physician. For external use only. OVERDOSAGE For management of a suspected drug overdose, contact your regional Poison Control Centre immediately. Percutaneous absorption of corticosteroids can occur, especially if used over a large area for prolonged periods of time.

If large amounts of corticosteroids are absorbed, toxic effects may include mild reversible suppression of adrenal function, ecchymoses of the skin, peptic ulceration, hypertension, aggravation of infections, hirsutism, acne, edema and muscle weakness due to protein depletion.

Prolonged use of large amounts of TEVA-TRIACOMB would likely increase the absorption of neomycin which in turn would enhance the potential for nephrotoxicitiy and ototoxicity as well as ulceration. No specific antidote is available, treatment should be primarily symptomatic and administration of the cream discontinued.